Abstract:Purpose/Objective(s) Recent research has categorized the genetic make-up of head and neck squamous cell cancers (HNSCC) at initial presentation. However, despite advances in treatment, up to 50% of patients develop a recurrent/metastatic (R/M) disease, with a significant decline in survival at that time. Here, we aim to analyze the genetic composition of patients with R/M HNSCC to establish the most frequent alterations in this population and determine if there are associations with survival. Materials/Methods We performed an IRB-approved retrospective analysis of patients with confirmed recurrences of head and neck cancer after treatment for curative intent. We collected clinical data from one institution's electronic health records. Patients were grouped into cancer locations [oropharynx, oral cavity, hypopharynx, larynx, nasopharynx]. Targeted DNA sequencing of the tumor samples was performed by Tempus. R square analysis was done to compare tumor genetic make-up. Results To date, a total of 44 patients with head and neck cancer recurrences were included in the analysis. 43.5% of patients had oral cavity cancer, and 32.6% of patients had oropharynx cancer. Seventeen patients (39%) were p16 positive. The median age at the time of diagnosis was 62.5 years (range 36-82), and the majority of patients were male (n=28, 64%). Twenty-four patients (54%) had a current or former smoking history. The median overall survival time was 721 days from the date of diagnosis. The median disease-free survival was 198 days. Survival rate of the entire cohort was 27.2% at the time of analysis. The most common mutation seen in the cohort was TP53, which was present in 29 patients (65%) and was associated with worse overall and disease-free survival. TERT and CDKN2A mutations were seen in 16 patients (36%), but were not associated with outcomes in this small sample size. Notably, both TERT and CDKN2A mutations are less common for the primary HNSCC diagnosis. Additional alterations were noted in PIK3CA (found in 20% of patients) and LRP1B (found in 9% of patients); while the former is associated with better overall survival, the latter was strongly associated with worse disease-free survival. Conclusion In the analysis of the R/M HNSCC cases, we identified genomic alterations similar to those found during primary diagnosis. While HNSCC cancers are genetically heterogeneous, alterations in TP53 remain the most commonly noted. R/M HNSCC populations commonly have CDKN2A and TERT mutations that are rarely found in primary diagnosis. In addition, mutations in LRP1B were associated with worse disease-free survival. Further analysis is ongoing to define the correlation between the mutational landscape of our patients and their response to therapy.

The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors: A systematic review and meta-analysis

Influence of Primary Tumor Resection on Survival of Patients with Metastatic Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Analysis

ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: A meta-analysis

Site-specific Therapy in Cancers of Unknown Primary Site: a Systematic Review and Meta-Analysis

Anti-PD-(L)1-Based Neoadjuvant Therapy in Head and Neck Carcinoma: a Meta-analysis of Prospective Clinical Trials.

EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma

Egfr and Her2 Expression in Primary Cervical Cancers and Corresponding Lymph Node Metastases: Implications for Targeted Radiotherapy

Prognostic impact of regulatory T cell in head and neck squamous cell carcinoma: A systematic review and meta-analysis

Effect of primary site and treatment modality of patients with head and neck myoepithelial carcinoma on survival

Clinicopathological and prognostic significance of EGFR over-expression in esophageal squamous cell carcinoma: a meta-analysis.

Is E-cadherin immunoexpression a prognostic factor for head and neck squamous cell carcinoma (HNSCC)? A systematic review and meta-analysis

Inflammatory markers as prognostic markers in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Evaluating the efficacy and safety of different neoadjuvant immunotherapy combinations in locally advanced HNSCC: a systematic review and meta-analysis

Prognostic value of FGFR1 expression and amplification in patients with HNSCC: A systematic review and meta-analysis

Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials

The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis

An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC

Neoadjuvant Chemotherapy of Cisplatin and Fluorouracil Regimen in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis

The Role of Radiotherapy to the Primary Site in Oropharyngeal Cancer with Limited Metastases—An Analysis of a Hospital-Based Registry

Prognostic Significance of PD-L1 Expression in Patients with Head and Neck Squamous Cell Carcinoma

Tumor Genomics and the Association with Survival in Recurrent/metastatic Head and Neck Cancer Patients